LifeMD (LFMD) to Release Earnings on Monday

LifeMD (NASDAQ:LFMD) is expected to post its quarterly earnings results after the market closes on Monday, March 10th. Analysts expect LifeMD to post earnings of ($0.04) per share and revenue of $57.43 million for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

LifeMD Trading Up 4.8 %

LFMD stock opened at $5.26 on Monday. The stock’s fifty day simple moving average is $5.68 and its two-hundred day simple moving average is $5.39. LifeMD has a 1-year low of $3.99 and a 1-year high of $12.88. The stock has a market cap of $227.82 million, a P/E ratio of -8.22 and a beta of 1.50.

Insider Activity at LifeMD

In related news, CEO Justin Schreiber sold 50,000 shares of the business’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $7.55, for a total transaction of $377,500.00. Following the sale, the chief executive officer now directly owns 2,653,715 shares in the company, valued at approximately $20,035,548.25. The trade was a 1.85 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 15.97% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on LFMD shares. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of LifeMD in a research report on Monday, November 11th. Lake Street Capital initiated coverage on LifeMD in a research note on Tuesday, December 10th. They issued a “buy” rating and a $12.00 target price on the stock. Mizuho initiated coverage on LifeMD in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $7.00 target price on the stock. Finally, KeyCorp lowered their target price on LifeMD from $10.00 to $7.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.14.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.